GlassScriptPhysician profile
Edward R Harkrader
NPI 1558374249
$15,306.71
in general payments reported to CMS, 2019-2025
42 companies · $1,967 in 2025
The $1,967 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,222 · 2020: $1,680 · 2021: $2,865 · 2022: $1,927 · 2023: $2,317 · 2024: $2,330 · 2025: $1,967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,499 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,499.44 |
| Education | $113.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,332.32 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,243.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,478.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,286.43 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,070.34 | 2019-2025 | |
| Astellas Pharma US INC | $896.38 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $739.64 | 2021-2025 | |
| Amarin Pharma, INC. | $639.24 | 2019-2021 | |
| Amgen INC. | $614.53 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $360.95 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $283.51 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $281.95 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $228.08 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $220.62 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $154.02 | 2019-2023 | Eliquis |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Harkrader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.